Ocugen Inc. (OCGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
OCGN Stock Price Chart Interactive Chart >
OCGN Price/Volume Stats
| Current price | $2.86 | 52-week high | $17.65 |
| Prev. close | $2.77 | 52-week low | $1.67 |
| Day low | $2.68 | Volume | 6,054,200 |
| Day high | $2.95 | Avg. volume | 9,139,308 |
| 50-day MA | $2.46 | Dividend yield | N/A |
| 200-day MA | $4.06 | Market Cap | 616.79M |
Ocugen Inc. (OCGN) Company Bio
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
Latest OCGN News From Around the Web
Below are the latest news stories about Ocugen Inc that investors may wish to consider to help them evaluate OCGN as an investment opportunity.
Ocugen Q4 2021 Earnings PreviewOcugen (NASDAQ:OCGN) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close. The consensus EPS Estimate is -$0.07 and the consensus Revenue Estimate is $0M. Ahead of its earnings, Ocugen announced a capital raise of $53.5M. Last week, Ocugen announced that the U.S. FDA lifted the... |
Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The CourseInvestment Thesis Ocugen (OCGN) stock has been sinking like a stone since the turn of the year - at the time of writing, it's down >60% in the past three months. This week, the FDA lifted its clinical hold on Ocugen's Investigational New Drug ("IND") application for Covaxin - a... |
Ocugen expects $53.5M from stock sale amid efforts to bring Covaxin to the U.S.Ocugen is continuing its efforts to bring a Covid-19 vaccine developed in India to the United States. |
3 Growth Stocks With Monster Upside of 253% to 650%, According to Wall StreetSelect analysts and investment banks are looking for these fast-growing stocks to skyrocket in 2022. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, trader! |
OCGN Price Returns
| 1-mo | -7.74% |
| 3-mo | 43.00% |
| 6-mo | -18.52% |
| 1-year | -63.61% |
| 3-year | -74.44% |
| 5-year | -97.35% |
| YTD | -37.14% |
| 2021 | 148.63% |
| 2020 | 251.92% |
| 2019 | -90.37% |
| 2018 | -95.61% |
| 2017 | 22.75% |
Loading social stream, please wait...